Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Exploring Pre-B Cell Receptor Signalling As a Therapeutic Target in Acute Lymphoblastic Leukaemia

Ali Alhammer, M.Sc, Marian Case, MSc, Helen J Blair, PhD, Josef Vormoor, MD FRCPCH, Julie Irving, PhD

Blood (2016) 128 (22): 4066.

https://doi.org/10.1182/blood.V128.22.4066.4066

Published: 2016

Journal Articles

Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation

Lynsey McKenzie, PhD, Natalia Martinez-Soria, PhD, Julia Draper, DPhil, Sirintra Nakjang, PhD, Helen J Blair, PhD, Christian Wichmann, MD, Josef Vormoor, MD FRCPCH, Constanze Bonifer, PhD, Georges Lacaud, PhD, Olaf Heidenreich, PhD

Blood (2016) 128 (22): 835.

https://doi.org/10.1182/blood.V128.22.835.835

Published: 2016

Journal Articles

High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity

Alex Elder, PhD, Helen Blair, PhD, Katherine Dormon, Simon Bomken, PhD MBBS, Simon J Cockell, PhD, Olaf Heidenreich, PhD, Josef Vormoor, MD FRCPCH

Blood (2015) 126 (23): 844.

https://doi.org/10.1182/blood.V126.23.844.844

Published: 2015

Journal Articles

A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse

Katherine Dormon, MSci, Elda S Latif, PhD, Matthew Bashton, PhD, Deepali Pal, PhD, Matthew Selby, MSci, Helen Blair, PhD, Vikki Rand, PhD, Andrew G Hall, PhD, Josef Vormoor, MD FRCPCH, Olaf Heidenreich, PhD

Blood (2015) 126 (23): 2619.

https://doi.org/10.1182/blood.V126.23.2619.2619

Published: 2015

Journal Articles

A Genome-Wide RNAi Screen to Identify Novel Genes Involved in Clonal Maintenance of ALL

Frida Ponthan, PhD, Simon Bomken, PhD MBBS, Deepali Pal, PhD, Alex Elder, PhD, Hesta McNeill, Josef Vormoor, MD FRCPCH, Olaf Heidenreich, PhD

Blood (2014) 124 (21): 2390.

https://doi.org/10.1182/blood.V124.21.2390.2390

Published: 2014

Journal Articles

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Natalie Bell, PhD, Helen J Blair, PhD, Josef Vormoor, MD FRCPCH, Chris Bacon, MBChB, PhD, Vikki Rand, PhD, Olaf Heidenreich, PhD, Simon Bomken, PhD MBBS

Blood (2014) 124 (21): 5501.

https://doi.org/10.1182/blood.V124.21.5501.5501

Published: 2014

Journal Articles

Significance of Fusion Genes for Maintenance of Leukaemia

Frida Ponthan, PhD, Hesta McNeill, Lars Buechler, PhD, Vasily Grinev, PhD, Josef Vormoor, MD, FRCPCH, Olaf Heidenreich, PhD

Blood (2011) 118 (21): 2455.

https://doi.org/10.1182/blood.V118.21.2455.2455

Published: 2011

Journal Articles

Disease Propagating Blasts in Standard and High Risk Acute Lymphoblastic Leukemia Are Frequent and of Diverse Immunophenotype.

Klaus Rehe, MD, Kerrie Wilson, BSc, (Hons), Hesta McNeill, Martin Schrappe, MD, Julie Irving, PhD, Josef Vormoor, MD, FRCPCH

Blood (2009) 114 (22): 1421.

https://doi.org/10.1182/blood.V114.22.1421.1421

Published: 2009

Journal Articles

CD19-Redirected Cytotoxic T Cells Prevent Engraftment of Primary Human Leukemia Cells In Vivo.

Silke Landmeier, PhD, Bianca Altvater, PhD, Sibylle Pscherer, Jutta Meltzer, Josef Vormoor, MD, FRCPCH, Juan F Vera, MD, Martin Pule, MD, Marc Hotfilder, PhD, Heribert Juergens, MD, Claudia Rossig, MD

Blood (2009) 114 (22): 3025.

https://doi.org/10.1182/blood.V114.22.3025.3025

Published: 2009

Journal Articles

In Childhood ALL, Both Blasts with a CD20 −/Low and a CD20 High Immunophenotype Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y −/− Mice.

Kerrie Wilson, BSc(Hons), Klaus Rehe, MD, Simon Bomken, MD, Marian Case, MSc, Leonard Shultz, PhD, Julie Irving, PhD, Josef Vormoor, MD, FRCPCH

Blood (2008) 112 (11): 1348.

https://doi.org/10.1182/blood.V112.11.1348.1348

Published: 2008

Journal Articles

MRD Monitoring of Childhood ALL Using Hierarchical Clustering and Support Vector Machine Learning of Complex Multi-Parameter Flow Cytometry Data.

Karel Fiser, PhD, Tomas Sieger, MSc, Angela Schumich, Julie Irving, PhD, Michael N Dworzak, MD, Josef Vormoor, MD, FRCPCH

Blood (2008) 112 (11): 1508.

https://doi.org/10.1182/blood.V112.11.1508.1508

Published: 2008

Journal Articles

The CD34 + CD38 Low CD19 + Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?

Kerrie Wilson, BSc(Hons), Marian Case, MSc, Lynne Minto, Simon Bailey, MD, PhD, FRCPCH, Josef Vormoor, MD, FRCPCH, Julie Irving, PhD

Blood (2008) 112 (11): 2505.

https://doi.org/10.1182/blood.V112.11.2505.2505

Published: 2008

NARROW

Exploring Pre-B Cell Receptor Signalling As a Therapeutic Target in Acute Lymphoblastic Leukaemia

Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation

High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity

A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse

A Genome-Wide RNAi Screen to Identify Novel Genes Involved in Clonal Maintenance of ALL

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Significance of Fusion Genes for Maintenance of Leukaemia

Disease Propagating Blasts in Standard and High Risk Acute Lymphoblastic Leukemia Are Frequent and of Diverse Immunophenotype.

CD19-Redirected Cytotoxic T Cells Prevent Engraftment of Primary Human Leukemia Cells In Vivo.

In Childhood ALL, Both Blasts with a CD20 −/Low and a CD20 High Immunophenotype Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y −/− Mice.

MRD Monitoring of Childhood ALL Using Hierarchical Clustering and Support Vector Machine Learning of Complex Multi-Parameter Flow Cytometry Data.

The CD34 + CD38 Low CD19 + Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only